# A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion

> **NCT04123886** · PHASE1 · COMPLETED · sponsor: **Sichuan Clover Biopharmaceuticals, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Malignant Pleural Effusion

## Interventions

- **DRUG:** SCB-313

## Key facts

- **NCT ID:** NCT04123886
- **Lead sponsor:** Sichuan Clover Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-08
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-03-31
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04123886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04123886, "A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04123886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*